- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06990880
- Oryginalna próba
Badanie GSK5458514 podawane samodzielnie lub w połączeniu z innymi środkami przeciwnowotworowymi u uczestników z rakiem przepływu
Faza 1/2 po raz pierwszy w humanie, otwarta, wieloośrodkowa, wieloośrodkowa, dawka i badanie ekspansji GSK5458514 PSMA ukierunkowane na samodzielne angażowanie komórek T lub w połączeniu z innymi środkami przeciwnowotworowymi u dorosłych uczestników z przerzutami raka prostaty (MCRPC)
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Przegląd badań
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Kopia zapasowa kontaktu do badania
- Nazwa: EU GSK Clinical Trials Call Center
- Numer telefonu: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Lokalizacje studiów
-
-
-
Lyon, Francja, 69373
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Armelle Vinceneux
-
Villejuif, Francja, 94805
- Rekrutacyjny
- GSK Investigational Site
-
Główny śledczy:
- Yohann Loriot
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Badajoz, Hiszpania, 06080
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Marta González Cordero
-
Barcelona, Hiszpania, 08023
- Rekrutacyjny
- GSK Investigational Site
-
Główny śledczy:
- Tatiana Hernandez
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Madrid, Hiszpania, 28040
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Bernard Doger
-
Madrid, Hiszpania, 28050
- Rekrutacyjny
- GSK Investigational Site
-
Główny śledczy:
- Emiliano Calvo Aller
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Málaga, Hiszpania, 29010
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Lucia Oliva Fernandez
-
Pozuelo de AlarcOn Madr, Hiszpania, 28223
- Rekrutacyjny
- GSK Investigational Site
-
Główny śledczy:
- VALENTINA BONI
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Kanagawa, Japonia, 232-0024
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Takashi Kawahara
-
Tokyo, Japonia, 104-0045
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Tatsunori Shimoi
-
Tokyo, Japonia, 135-8550
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Yuji Miura
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Daniel Khalaf
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3J1
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Ramy Saleh
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutacyjny
- GSK Investigational Site
-
Główny śledczy:
- April Rose
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85054
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Yousef Zakharia
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80218-1234
- Rekrutacyjny
- GSK Investigational Site
-
Główny śledczy:
- Gerald Falchook
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Daniel Petrylak
-
-
Minnesota
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Dan Childs
-
-
New Jersey
-
East Brunswick, New Jersey, Stany Zjednoczone, 08816
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Bruno Fang
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- Rekrutacyjny
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Numer telefonu: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Główny śledczy:
- Benjamin Garmezy
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Provide signed informed consent. Participants must be capable of providing informed consent, which includes compliance with the requirements and restrictions listed in the Informed consent form (ICF) and in this protocol.
- Male participants greater than equal to (>=)18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.
Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 195 days, after the last dose of study intervention:
Refrain from donating sperm
PLUS either:
Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
OR
Must agree to use contraception as detailed below:
Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.
-
Participants with mCRPC:
- Histologically or cytologically confirmed adenocarcinoma of the prostate
- Metastatic disease diagnosed either by radiologic imaging (Positron emission tomography [PET]- Computed tomography [CT]) and/or regular CT and/or Magnetic resonance imaging (MRI) and/or bone scan
- Castration-resistant status as per PCWG3 criteria
-
Has prior novel anti-androgen receptor therapy failure and had treatment failure with 1-2 taxane-based chemotherapy regimens including for metastatic hormone sensitive prostate cancer.
-
Has (1) at least 1 soft tissue target lesion per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) OR (2) if Non-Target soft tissue disease only per PCWG3-modified RECIST 1.1, may be included if a rise in Prostate-specific antigen (PSA) on 2 successive determinations at least 1 week apart (the most recent screening measurement must have been >= 2 nanograms per milliliter (ng/mL) with testosterone levels <50 nanograms per deciliter (ng/dL), OR (3) bone disease defined by PCWG3 (2 or more lesions on bone scan at screening), as determined by the investigator.
-
Documented disease progression on most recent systemic anti-cancer therapy defined by fulfilling at least 1 of the PCWG3 criteria
-
Have serum testosterone <50 ng/dL (<1.7 nM). Patients must have undergone bilateral orchiectomy or be on continuous androgen-deprivation therapy with a Gonadotropin-releasing hormone (GnRH) agonist or antagonist; this therapy must have been initiated at least 4 weeks prior to randomization and treatment must be continued throughout the study.
-
Eastern Cooperative Oncology Group (ECOG) performance status <=1, with no deterioration in the 2 weeks before step-up treatment period Day 1.
-
Have supplied tumor tissue from a newly obtained biopsy or archival tumor tissue for retrospective detection of Prostate-specific membrane antigen (PSMA) expression and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue preferably taken after the completion of the participant's last line of therapy prior to the first dose of study drug is acceptable.
-
Participants must have adequate organ function
Exclusion criteria:
-
Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any histology different from adenocarcinoma.
-
History of central nervous system (CNS) metastases or leptomeningeal disease.
-
Diagnosis of invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years, except as noted below:
- History of an invasive malignancy for which the participant was definitively treated, and in which the participant has been disease free for at least 2 years, and which, in the opinion of the principal investigator and medical monitor, is not expected to affect the evaluation of the effects of the study intervention on the currently targeted disease under study
- Curatively treated basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, and/or in situ breast cancer may be enrolled
-
Has ongoing adverse reaction(s) from prior therapy that have not recovered to <=Grade 1 or to the baseline status preceding prior therapy, excluding [e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.
-
Confirmed history or recurrent autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary).
-
Has evidence of interstitial lung disease, non-infectious pneumonitis, and/or a history of interstitial lung disease, non-infectious pneumonitis that required steroid.
-
Has received any anti-cancer therapy or prior systemic biologic therapy, including immunotherapy within 30 days prior to first dose of study intervention.
-
Prior PSMA radionuclide therapy within 2 months prior to GSK5458514 unless participant received <2 cycles.
-
Prior PSMA-Chimeric antigen receptor T cell therapy (CAR-T) cell therapy and PSMA (T cell engager) TCE/ Bispecific T cell engagers (BiTE) or other prostate Tumor-associated antigens (TAA) specific T cell engager (TCE).
-
Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.
-
Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
-
History of severe neurological or psychiatric disorder, including epilepsy, dementia, or major depression deemed to interfere with study assessments.
-
Has had any major surgery (such as craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks prior to first dose of study intervention.
-
Serious infections within 4 weeks prior to the first dose, including but not limited to infectious complications, bacteremia, severe pneumonia treated with IV antibiotics for >=2 weeks; active infections with therapeutic IV antibiotics within 2 weeks prior to the first dose or oral antibiotics within 1 week prior to the first dose. Participants who are receiving or have received prophylactic antibiotics (e.g., prophylaxis against urinary infections) are allowed.
Liver safety exclusion criteria:
- Has an Alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or >5x ULN if documented history of liver metastases.
- Has a total bilirubin value >1.5x ULN.
- Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
- Has documented presence of Hepatitis B surface antigen (HBsAg), at screening or within 3 months prior to the first dose of study intervention.
- Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to Cycle 1 Day 1 unless the participant can meet the following criteria: NOTE: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled if a confirmatory negative HCV RNA test is obtained and the participant otherwise meets entry criteria
- Has a positive HCV ribonucleic acid (RNA) test result at screening or within 3 months prior to the first dose of study intervention. NOTE: The HCV RNA test is optional, and participants with a negative HCV antibody test are not required to undergo HCV RNA testing as well.
- Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study, study procedures, restrictions, and requirements as determined by the investigator.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Część 1: Eskalacja dawki GSK5458514 Monoterapia
|
GSK5458514 will be administered. |
|
Eksperymentalny: Część 2: Rozszerzenie dawki monoterapii GSK5458514
|
GSK5458514 will be administered. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Liczba uczestników z toksycznością ograniczającą dawkę (DLT) w okresie obserwacji DLT
Ramy czasowe: Do 28 dni
|
Do 28 dni
|
|
Liczba uczestników z zdarzeniami niepożądanymi (AES), poważne zdarzenia niepożądane (SAE), według nasilenia
Ramy czasowe: Do około 29 miesięcy
|
Do około 29 miesięcy
|
|
Liczba uczestników z AES prowadzącą do modyfikacji dawki
Ramy czasowe: Do około 29 miesięcy
|
Do około 29 miesięcy
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Obszar pod stężeniem od 0 do t (AUC 0-T) GSK5458514
Ramy czasowe: Do około 32 miesięcy
|
Do około 32 miesięcy
|
|
|
Maksymalne stężenie (CMAX) GSK5458514
Ramy czasowe: Do około 32 miesięcy
|
Do około 32 miesięcy
|
|
|
Czas na maksymalne stężenie (TMAX) GSK5458514
Ramy czasowe: Do około 32 miesięcy
|
Do około 32 miesięcy
|
|
|
Liczba uczestników z przeciwciałami antykształtnymi (ADA) przeciwko GSK5458514
Ramy czasowe: Do około 32 miesięcy
|
Do około 32 miesięcy
|
|
|
Mian ADA przeciwko GSK5458514
Ramy czasowe: Do około 32 miesięcy
|
Do około 32 miesięcy
|
|
|
Prostate-specific Antigen Decrease From Baseline >=50% (PSA50) Response Rate
Ramy czasowe: Up to approximately 32 months
|
PSA50 response rate is defined as percentage of participants with a decrease of >=50% in the PSA concentration from the baseline PSA value, confirmed at least 3 weeks later. |
Up to approximately 32 months
|
|
Objective Response Rate (ORR)
Ramy czasowe: Up to approximately 32 months
|
ORR is defined as the percentage of participants in the ORR Evaluable set who have a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) per prostate cancer working group 3 (PCWG3) guidelines as assessed by investigator. |
Up to approximately 32 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: GSK Clinical Trials, GlaxoSmithKline
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 223050
- 2025-521581-10-00 (Ctis)
- 2025 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Ramy czasowe udostępniania IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Kryteria dostępu do udostępniania IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .